INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BTIG Downgrades INmune Bio Inc. (INMB) to Neutral
June 30, 2025 4:37 PM EDTBTIG analyst Thomas Shrader downgraded INmune Bio Inc. (NASDAQ: INMB) from Buy to Neutral.
The analyst comments "A solid MAYBE but with no clear way forward and management talking about moving to other programs - so NEUTRAL makes sense. The size of the AD opportunity hasn't changed, so the current stock price (about $2 all day) equates to a probability of success in AD of 0% with all revenues coming from MDD. Our two biggest worries going into this readout (preview HERE) were: 1) the modest enrichment in the MINDFul trial population, based on one (of four)... More
